Literature DB >> 17180607

[Photodynamic therapy of AMD for the first (better sight) and the second (worse sight) eyes].

A C Marti1, F K P Sutter, D Barthelmes, J C Fleischhauer, M M Kurz-Levin, M M Bosch, H Helbig.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) is the standard treatment procedure for many forms of exudative and/or neovascular AMD. Despite therapy, visual acuity often drops to low vision levels. The cost efficiency of treating the eye in which vision is worse is therefore the subject of some controversy. PATIENTS AND METHODS: A retrospective case-control study was conducted in all patients who were treated with PDT at the Universitätsspital Zürich between September 1999 and November 2004. Each patient's first (with worse vision) and second (with better vision) eyes were compared for situation on presentation and course during treatment.
RESULTS: In 117/228 cases (51.3%) visual acuity of the treated eye was better than (or identical to) that of the fellow eye at presentation. Visual acuity before therapy was an average of 0.58+/-0.27 logMAR [Snellen: 0.26 (0.14-0.49)] in the eyes with better visual acuity and 0.69+/-0.4 logMAR [Snellen 0.20 (0.08-0.51)] in the fellow eyes (p=0.015). After therapy there was no significant difference between the patient groups in visual acuity or in the magnitude of any change in visual acuity, or in lesion size or change in lesion size.
CONCLUSION: The outcome of PDT of a second eye (with better visual acuity) is not significantly better than the result obtained in the first eye (the one with worse visual acuity initially).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17180607     DOI: 10.1007/s00347-006-1447-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  24 in total

1.  Impact of age related macular degeneration on quality of life.

Authors:  J B Hassell; E L Lamoureux; J E Keeffe
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  Visual acuity measurements.

Authors:  Jack T Holladay
Journal:  J Cataract Refract Surg       Date:  2004-02       Impact factor: 3.351

Review 3.  The epidemiology of age-related macular degeneration.

Authors:  Johanna M Seddon; Clara A Chen
Journal:  Int Ophthalmol Clin       Date:  2004

4.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

5.  The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.

Authors:  Gary C Brown; Melissa M Brown; Joseph Campanella; George R Beauchamp
Journal:  Am J Ophthalmol       Date:  2005-10       Impact factor: 5.258

6.  Clinical outcome and subjective quality of life after photodynamic therapy in patients with age-related macular degeneration.

Authors:  F Krummenauer; M Braun; H B Dick
Journal:  Eur J Ophthalmol       Date:  2005 Jan-Feb       Impact factor: 2.597

7.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

8.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

Authors:  Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

9.  [Visual acuity, quality of life, and patient satisfaction after PDT treatment in AMD patients].

Authors:  F Krummenauer; M Braun; H B Dick
Journal:  Ophthalmologe       Date:  2004-07       Impact factor: 1.059

10.  Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'.

Authors:  R M Barnes; L Gee; S Taylor; M C Briggs; S P Harding
Journal:  Eye (Lond)       Date:  2004-08       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.